Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Immunoprecipitation

Immunoprecipitation

Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes.

Gene therapy·2014

Same author

Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.

Vaccine·2011

Same author

Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.

British journal of pharmacology·2010

Same author

Virostatics: a new class of anti-HIV drugs.

Current medicinal chemistry·2007

Same author

Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.

Antiviral therapy·2005

Same author

Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.

AIDS research and human retroviruses·2005

Search research articles

Related Experiment Video

Updated: Jun 30, 2026

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

Nanochemistry-based immunotherapy for HIV-1.

F Lori¹, S A Calarota, J Lisziewicz

¹Research Institute for Genetic and Human Therapy, Pavia, Italy.

Current Medicinal Chemistry

|August 21, 2007

Summary

DermaVir Patch, a novel nanomedicine, aims to induce long-lasting HIV-specific T-cell responses for HIV/AIDS immunotherapy. This approach complements drug therapy by potentially controlling viral replication through enhanced cellular immunity.

More Related Videos

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Experiment Videos

Last Updated: Jun 30, 2026

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Area of Science:

Immunology
Nanomedicine
Virology

Background:

Highly active antiretroviral treatment (HAART) improves outcomes for HIV-1 but cannot eradicate the virus or restore HIV-specific immunity.
Cell-mediated immunity shows potential in controlling viral replication and slowing disease progression in HIV-1 infection.
There is a need for immunotherapies that induce durable HIV-specific T-cell responses to complement existing treatments.

Purpose of the Study:

To review the antiviral activity of cellular immunity induced by DermaVir Patch.
To discuss the role of molecular adjuvants and cytokine plasmid DNA in enhancing DermaVir's immunotherapeutic potential for HIV/AIDS.

Main Methods:

DermaVir Patch utilizes an HIV-1 antigen-encoding plasmid DNA formulated in nanoparticles.
The patch is applied to skin, facilitating nanoparticle delivery to Langerhans cells (LC) for transport to lymph nodes.
LC mature into dendritic cells (DC) to present antigens and induce T-cell responses.

Main Results:

Pre-clinical studies and Phase I clinical trials indicate DermaVir Patch is safe and well-tolerated in individuals with HIV-1.
DermaVir Patch has demonstrated potential for inducing cellular immunity against HIV-1.

Conclusions:

DermaVir Patch represents a promising nanomedicine platform for HIV/AIDS immunotherapy.
Further research into adjuvant combinations could enhance the efficacy of DermaVir-induced cellular immunity.